PSIL-002
PSIL-002 is a non-hallucinogenic serotonin 5-HT1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders. Its route of administration is unspecified. The drug's effects in animals have been described. PSIL-002 is being developed by Psilera. As of August 2022, it is in the preclinical research stage of development for all indications. The drug is an analogue of dimethyltryptamine, but its exact chemical structure does not yet seem to have been disclosed.